Home
IMCR
IMCR News

Latest Immunocore Holdings plc (IMCR) News on February 22, 2025

Lilly’s former M&A chief scours the landscape for potential deals as Immunocore’s new CFO

Pharma Voice

2 days ago

Lilly’s former M&A chief scours the landscape for potential deals as Immunocore’s new CFO

Immunocore to report fourth quarter and full year 2024 financial results and host call on February 26, 2025

GlobeNewswire

3 days ago

Immunocore to report fourth quarter and full year 2024 financial results and host call on February 26, 2025

Immunocore Gears Up to Report Q4 Earnings: Is a Beat in Store?

Zacks

5 days ago

Immunocore Gears Up to Report Q4 Earnings: Is a Beat in Store?

Wall Street Analysts Believe Immunocore (IMCR) Could Rally 113.13%: Here's is How to Trade

Zacks

a month ago

Wall Street Analysts Believe Immunocore (IMCR) Could Rally 113.13%: Here's is How to Trade

Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

a month ago

Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference

Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

2 months ago

Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference

MT Newswires

2 months ago

Immunocore Names Travis Coy Chief Financial Officer

Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development

GlobeNewswire

2 months ago

Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development

MT Newswires

2 months ago

Immunocore Doses First Patient in Phase 1 Trial of Potential Cancer Treatment

Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME

GlobeNewswire

2 months ago

Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME

Immunocore doses first subject in gastrointestinal cancer therapy trial

Clinical Trials Arena

2 months ago

Immunocore doses first subject in gastrointestinal cancer therapy trial

Immunocore announces treatment of first patient in the Phase 1/2 trial of IMC-R117C targeting PIWIL1 in advanced gastrointestinal cancers

GlobeNewswire

2 months ago

Immunocore announces treatment of first patient in the Phase 1/2 trial of IMC-R117C targeting PIWIL1 in advanced gastrointestinal cancers

Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?

Benzinga

2 months ago

Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?

MT Newswires

2 months ago

Morgan Stanley Downgrades Immunocore Holdings to Equalweight From Overweight, Cuts Price Target to $35 From $74

All You Need to Know About Immunocore (IMCR) Rating Upgrade to Strong Buy

Zacks

2 months ago

All You Need to Know About Immunocore (IMCR) Rating Upgrade to Strong Buy

Immunocore, EORTC announce enrollment of first patient in Phase 3 ATOM trial

TipRanks

2 months ago

Immunocore, EORTC announce enrollment of first patient in Phase 3 ATOM trial

MT Newswires

2 months ago

Immunocore Enrolls First Patient in Phase 3 Uveal Melanoma Trial

EORTC and Immunocore announce enrolment of first patient onto the only active Phase 3 adjuvant trial in uveal melanoma

GlobeNewswire

2 months ago

EORTC and Immunocore announce enrolment of first patient onto the only active Phase 3 adjuvant trial in uveal melanoma

MT Newswires

3 months ago

Immunocore Says UK NICE Recommends Kimmtrak for Funding Through National Health Service in England

Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma

GlobeNewswire

3 months ago

Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma

Does Immunocore (IMCR) Have the Potential to Rally 112.82% as Wall Street Analysts Expect?

Zacks

3 months ago

Does Immunocore (IMCR) Have the Potential to Rally 112.82% as Wall Street Analysts Expect?

Immunocore Holdings plc (IMCR): This Small-Cap Stock Is Ready To Explode

Insider Monkey

3 months ago

Immunocore Holdings plc (IMCR): This Small-Cap Stock Is Ready To Explode

Is Immunocore Holdings plc (IMCR) the Best Immunotherapy Stock to Buy Now?

Insider Monkey

3 months ago

Is Immunocore Holdings plc (IMCR) the Best Immunotherapy Stock to Buy Now?

Wall Street Analysts Predict an 112.56% Upside in Immunocore (IMCR): Here's What You Should Know

Zacks

3 months ago

Wall Street Analysts Predict an 112.56% Upside in Immunocore (IMCR): Here's What You Should Know

Immunocore to present at upcoming investor conferences

GlobeNewswire

3 months ago

Immunocore to present at upcoming investor conferences

Immunocore reports third quarter financial results and provides a business update

GlobeNewswire

4 months ago

Immunocore reports third quarter financial results and provides a business update

Immunocore (IMCR) Upgraded to Buy: Here's Why

Zacks

4 months ago

Immunocore (IMCR) Upgraded to Buy: Here's Why

MT Newswires

4 months ago

--UBS Initiates Immunocore Holdings With Sell Rating, $24 Price Target

Immunocore Holdings PLC (IMCR) Q2 2024 Earnings Call Highlights: Strong US Growth and Strategic ...

GuruFocus.com

4 months ago

Immunocore Holdings PLC (IMCR) Q2 2024 Earnings Call Highlights: Strong US Growth and Strategic ...

Immunocore Holdings plc (IMCR): Worst 52-Week Low Stock to Buy Now

Insider Monkey

5 months ago

Immunocore Holdings plc (IMCR): Worst 52-Week Low Stock to Buy Now

Immunocore Holdings plc (NASDAQ:IMCR) Ranks Low On The List Of Worst Falling Stocks To Buy

Insider Monkey

5 months ago

Immunocore Holdings plc (NASDAQ:IMCR) Ranks Low On The List Of Worst Falling Stocks To Buy

Immunocore Holdings plc (IMCR) Hits 52-Week Low Despite 34% Surge in KIMMTRAK Sales

Insider Monkey

5 months ago

Immunocore Holdings plc (IMCR) Hits 52-Week Low Despite 34% Surge in KIMMTRAK Sales

Immunocore Holdings plc (IMCR): Short Seller Sentiment is Bearish on This Cancer Stock

Insider Monkey

5 months ago

Immunocore Holdings plc (IMCR): Short Seller Sentiment is Bearish on This Cancer Stock

Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer

GlobeNewswire

5 months ago

Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer

Immunocore to present at the 2024 Cantor Global Healthcare Conference

GlobeNewswire

5 months ago

Immunocore to present at the 2024 Cantor Global Healthcare Conference

Significant Portfolio Addition: T. Rowe Price Investment Management, Inc. ...

GuruFocus.com

5 months ago

Significant Portfolio Addition: T. Rowe Price Investment Management, Inc. ...

Immunocore Holdings plc (IMCR): Top ADR Stock According to Hedge Funds

Insider Monkey

6 months ago

Immunocore Holdings plc (IMCR): Top ADR Stock According to Hedge Funds

MT Newswires

6 months ago

Immunocore Finance Chief Brian Di Donato to Resign

Immunocore announces transition of Chief Financial Officer

GlobeNewswire

6 months ago

Immunocore announces transition of Chief Financial Officer

MT Newswires

6 months ago

Mizuho Adjusts Immunocore Holdings' PT to $72 From $88, Keeps Outperform Rating

The Immunocore Holdings plc (NASDAQ:IMCR) Second-Quarter Results Are Out And Analysts Have Published New Forecasts

Simply Wall St.

6 months ago

The Immunocore Holdings plc (NASDAQ:IMCR) Second-Quarter Results Are Out And Analysts Have Published New Forecasts

MT Newswires

6 months ago

Immunocore Shares Rise After Reporting Narrower Q2 Net Loss, Higher Revenue

Immunocore reports second quarter financial results and provides a business update

GlobeNewswire

6 months ago

Immunocore reports second quarter financial results and provides a business update

Immunocore to report second quarter 2024 financial results and host call on August 8, 2024

GlobeNewswire

7 months ago

Immunocore to report second quarter 2024 financial results and host call on August 8, 2024

Is There An Opportunity With Immunocore Holdings plc's (NASDAQ:IMCR) 32% Undervaluation?

Simply Wall St.

7 months ago

Is There An Opportunity With Immunocore Holdings plc's (NASDAQ:IMCR) 32% Undervaluation?

MT Newswires

8 months ago

Immunocore Randomizes First Patient in Phase 3 Trial of Cutaneous Melanoma Combination Treatment

Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma

GlobeNewswire

8 months ago

Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma

Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition

Business Wire

8 months ago

Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition

Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus

GlobeNewswire

8 months ago

Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus

Share buy-back programme - week 23

GlobeNewswire

8 months ago

Share buy-back programme - week 23

Do Scientex Berhad's (KLSE:SCIENTX) Earnings Warrant Your Attention?

Simply Wall St.

8 months ago

Do Scientex Berhad's (KLSE:SCIENTX) Earnings Warrant Your Attention?

Japan's service sector mood hits nearly 2-year low in May

Reuters

8 months ago

Japan's service sector mood hits nearly 2-year low in May

N. Korea sends more balloons as Kim's sister warns of 'new counteraction'

AFP

8 months ago

N. Korea sends more balloons as Kim's sister warns of 'new counteraction'

Enduring role of 'treasuring the past' hailed

PR Newswire

8 months ago

Enduring role of 'treasuring the past' hailed

Velcan Holdings: buyback offer of 500 000 shares at Eur 14.5 per share

GlobeNewswire

8 months ago

Velcan Holdings: buyback offer of 500 000 shares at Eur 14.5 per share

Dow Jones Falls On Jobs Report; GameStop Plunges Ahead Of 'Roaring Kitty' Live Event

Investor's Business Daily

8 months ago

Dow Jones Falls On Jobs Report; GameStop Plunges Ahead Of 'Roaring Kitty' Live Event

Can DocuSign's AI offering accelerate growth?

Yahoo Finance Video

8 months ago

Can DocuSign's AI offering accelerate growth?

Lab-on-a-Chip and Microfluidics World Congress 2024: 3-Day Conference (Laguna Hills, United States - November 18-20, 2024) Covering Technologies, Companies and Commercialization

GlobeNewswire

8 months ago

Lab-on-a-Chip and Microfluidics World Congress 2024: 3-Day Conference (Laguna Hills, United States - November 18-20, 2024) Covering Technologies, Companies and Commercialization

Analysis-Mexico investors worry lopsided vote could threaten rule of law

Reuters

8 months ago

Analysis-Mexico investors worry lopsided vote could threaten rule of law

AI Boom Giving Taiwan Semiconductor Sales A Boost

Investor's Business Daily

8 months ago

AI Boom Giving Taiwan Semiconductor Sales A Boost

Taxes Served Corp. Acquires Blue Mountain Bookkeeping LLC to Enhance Tax and Bookkeeping Services

PR Newswire

8 months ago

Taxes Served Corp. Acquires Blue Mountain Bookkeeping LLC to Enhance Tax and Bookkeeping Services

Smart Irrigation Market worth $3.0 billion by 2029 - Exclusive Report by MarketsandMarkets™

PR Newswire

8 months ago

Smart Irrigation Market worth $3.0 billion by 2029 - Exclusive Report by MarketsandMarkets™

Business Wire

8 months ago

Airstar Bank, with AMTD as a co-founder, successfully introduces Futu as A New Shareholder

Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response

GlobeNewswire

9 months ago

Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response

Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024

GlobeNewswire

9 months ago

Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024

Immunocore to present at the Jefferies Global Healthcare Conference

GlobeNewswire

9 months ago

Immunocore to present at the Jefferies Global Healthcare Conference

MT Newswires

9 months ago

Immunocore Converts Skin Cancer Therapy Phase 2/3 Trial to Phase 3

Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma

GlobeNewswire

9 months ago

Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma

Cancer Biotech Stocks Are on the Move Ahead of a Big Event. What to Know.

Barrons.com

9 months ago

Cancer Biotech Stocks Are on the Move Ahead of a Big Event. What to Know.

Analysts Have Made A Financial Statement On Immunocore Holdings plc's (NASDAQ:IMCR) First-Quarter Report

Simply Wall St.

9 months ago

Analysts Have Made A Financial Statement On Immunocore Holdings plc's (NASDAQ:IMCR) First-Quarter Report

MT Newswires

9 months ago

Immunocore Holdings' Shares Fall After Q1 Net Loss Widens

Immunocore Holdings PLC Reports Q1 2024 Earnings: Misses EPS Estimates, Surpasses Revenue Forecasts

GuruFocus.com

9 months ago

Immunocore Holdings PLC Reports Q1 2024 Earnings: Misses EPS Estimates, Surpasses Revenue Forecasts

Immunocore reports first quarter financial results and provides a business update

GlobeNewswire

9 months ago

Immunocore reports first quarter financial results and provides a business update

MT Newswires

10 months ago

Leerink Partners Starts Immunocore Holdings With Outperform Rating, $74 Price Target

Immunocore announces upcoming presentation and posters at ASCO 2024

GlobeNewswire

10 months ago

Immunocore announces upcoming presentation and posters at ASCO 2024

Immunocore to present at upcoming investor conferences

GlobeNewswire

a year ago

Immunocore to present at upcoming investor conferences

Immunocore presented two posters at CROI 2024

GlobeNewswire

a year ago

Immunocore presented two posters at CROI 2024

Immunocore to present at upcoming investor conferences

GlobeNewswire

a year ago

Immunocore to present at upcoming investor conferences

Immunocore Holdings Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

a year ago

Immunocore Holdings Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags

Immunocore Holdings plc (NASDAQ:IMCR) Q4 2023 Earnings Call Transcript

Insider Monkey

a year ago

Immunocore Holdings plc (NASDAQ:IMCR) Q4 2023 Earnings Call Transcript

Immunocore Holdings PLC (IMCR) Reports Strong Revenue Growth Amidst Expansion and Clinical ...

GuruFocus.com

a year ago

Immunocore Holdings PLC (IMCR) Reports Strong Revenue Growth Amidst Expansion and Clinical ...

Immunocore reports fourth quarter and full year 2023 financial results and provides a business update

GlobeNewswire

a year ago

Immunocore reports fourth quarter and full year 2023 financial results and provides a business update

Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial

GlobeNewswire

a year ago

Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial

Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024

GlobeNewswire

a year ago

Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024

Sarepta's (SRPT) DMD Drug sBLA Gets FDA's Priority Tag, Stock Up

Zacks

a year ago

Sarepta's (SRPT) DMD Drug sBLA Gets FDA's Priority Tag, Stock Up

Zacks Industry Outlook Highlights Sarepta, Exelixis, Immunocore, Editas and Puma Biotechnology

Zacks

a year ago

Zacks Industry Outlook Highlights Sarepta, Exelixis, Immunocore, Editas and Puma Biotechnology

Zoetis' (ZTS) Q4 Earnings Miss Expectations, Sales Beat

Zacks

a year ago

Zoetis' (ZTS) Q4 Earnings Miss Expectations, Sales Beat

5 Biotech Stocks to Consider for Your Portfolio in 2024

Zacks

a year ago

5 Biotech Stocks to Consider for Your Portfolio in 2024

Immunovant (IMVT) Up 3% as Q3 Earnings Top, Pipeline in Focus

Zacks

a year ago

Immunovant (IMVT) Up 3% as Q3 Earnings Top, Pipeline in Focus

Humacyte (HUMA) Up on HAV BLA Priority Tag for Vascular Trauma

Zacks

a year ago

Humacyte (HUMA) Up on HAV BLA Priority Tag for Vascular Trauma

REGENXBIO's (RGNX) Hunter Syndrome Study Meets Goal, Stock Up

Zacks

a year ago

REGENXBIO's (RGNX) Hunter Syndrome Study Meets Goal, Stock Up

Immunome (IMNM) to Acquire Desmoid Tumor Candidate, Stock Up

Zacks

a year ago

Immunome (IMNM) to Acquire Desmoid Tumor Candidate, Stock Up

Deciphera (DCPH) Q4 Loss Narrower Than Expected, Revenues Beat

Zacks

a year ago

Deciphera (DCPH) Q4 Loss Narrower Than Expected, Revenues Beat

Squarespace (SQSP) Rises But Trails Market: What Investors Should Know

Zacks

a year ago

Squarespace (SQSP) Rises But Trails Market: What Investors Should Know

Associated Press Finance

a year ago

Post Holdings: Fiscal Q1 Earnings Snapshot

Post (NYSE:POST) Surprises With Q1 Sales

StockStory

a year ago

Post (NYSE:POST) Surprises With Q1 Sales

Morningstar Research

a year ago

Analyst Report: Janus Henderson Group plc

Janus Henderson Group PLC Reports Solid Growth in Q4 and Full-Year 2023 Earnings

GuruFocus.com

a year ago

Janus Henderson Group PLC Reports Solid Growth in Q4 and Full-Year 2023 Earnings

Surging Earnings Estimates Signal Upside for Celestica (CLS) Stock

Zacks

a year ago

Surging Earnings Estimates Signal Upside for Celestica (CLS) Stock

Schneider National (SNDR) Misses Q4 Earnings Estimates

Zacks

a year ago

Schneider National (SNDR) Misses Q4 Earnings Estimates

Share on Social Networks: